All symptomatic CMV disease · solid organ transplant recipients
Antiviral prophylaxis leads to lower CMV disease: all symptomatic CMV disease compared with placebo or no treatment (high certainty).
1 finding from 1 review
Death associated with CMV disease · solid organ transplant recipients
Antiviral prophylaxis probably leads to lower death due to CMV disease compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
All‐cause death · solid organ transplant recipients
Antiviral prophylaxis leads to lower all‐cause death compared with placebo or no treatment (high certainty).
1 finding from 1 review
CMV infection · solid organ transplant recipients
Antiviral prophylaxis leads to lower CMV infection compared with placebo or no treatment (high certainty).
1 finding from 1 review
Graft loss · solid organ transplant recipients
Antiviral prophylaxis showed no clear difference in graft loss compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Acute rejection · solid organ transplant recipients
Antiviral prophylaxis showed no clear difference in acute rejection compared with placebo or no treatment (high certainty).
1 finding from 1 review
Leucopenia · solid organ transplant recipients
Antiviral prophylaxis showed no clear difference in leucopenia compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Kidney dysfunction · solid organ transplant recipients
Antiviral prophylaxis showed no clear difference in kidney dysfunction compared with placebo or no treatment (low certainty).
1 finding from 1 review
Intervention not reported
Interferon vs. control · patients undergoing liver transplantation for chronic hepatitis C viral infection.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
90‐day mortality · patients undergoing liver transplantation for chronic hepatitis C viral infection.
It is very uncertain whether the intervention changes 90‐day mortality (very low certainty).
1 finding from 1 review
Intervention not reported
Mortality at maximal · patients undergoing liver transplantation for chronic hepatitis C viral infection.
It is very uncertain whether the intervention changes mortality at maximal (very low certainty).
1 finding from 1 review
Intervention not reported
Mortality (HR) · patients undergoing liver transplantation for chronic hepatitis C viral infection.
It is very uncertain whether the intervention changes mortality (HR) (very low certainty).
1 finding from 1 review
Intervention not reported
HCV antibody vs. placebo · patients undergoing liver transplantation for chronic hepatitis C viral infection.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Interferon vs. control · patients undergoing liver transplantation for chronic hepatitis C viral infection.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Retransplantation at maximal · patients undergoing liver transplantation for chronic hepatitis C viral infection.
It is very uncertain whether the intervention changes retransplantation at maximal (very low certainty).
1 finding from 1 review
Intervention not reported
HCV antibody vs. placebo · patients undergoing liver transplantation for chronic hepatitis C viral infection.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
90‐day retransplantation · patients undergoing liver transplantation for chronic hepatitis C viral infection.
It is very uncertain whether the intervention changes 90‐day retransplantation (very low certainty).
1 finding from 1 review